Common Stock, par value $0.001 per share
- Symbol
- CODX
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 2.02, 7.01, 9.01 · 8-K
Co-Diagnostics, Inc.
CODXNASDAQEQUITYCurrent
Results of Operations and Financial Condition · Regulation FD Disclosure
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description: No.: ────────────────────────────────────────────────────────────────────────────────────── 99.1 Press Release, dated November 10, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Press release in this filing
Co-Diagnostics Reports Third Quarter 2026 Financial Results →Company context
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
Current securities
Registered securities in this filing
CO-DIAGNOSTICS, INC. · 8-K · Filed 2026-11-10
Disclosure sections
Item 9.01Item 9.01 - Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit Description:
No.:
──────────────────────────────────────────────────────────────────────────────────────
99.1 Press Release, dated November 10, 2026
104 Cover
Page Interactive Data File (embedded within the Inline XBRL document)
Filed exhibits (1)
Exhibit 99.1 Co-Diagnostics Reports Third Quarter 2026 Financial Results Two Regulatory Submissions Under Review in India and the U.S. Third Quarter Operating Expenses Down 12% Year Over Year Platform Capabilities Expanding with ReadyGo Collaboration, India Connectivity and Vector Smart Growth SALT LAKE CITY, November 10, 2026 - Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Dx” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Business Highlights: Submitted a 510(k) premarket notification and concurrent CLIA Waiver by Application in August to the U.S. Food and Drug Administration (FDA) for the Co-Dx PCR Flu A/B & RSV test on the Co-Dx PCR Pro instrument, supported by a clinical study of more than 1,400 symptomatic patients at nine U.S. clinical sites Entered a collaboration with ReadyGo Diagnostics to evaluate blood-based molecular testing at the point of need, with an initial focus on decentralized Ebola detection Completed a proof-of-concept study in July in which an ex…
Open exhibit ↗